Where to buy CJC-1295.

There are two molecules sold under the name CJC-1295, and they aren’t the same drug. One has a 30-minute half-life. The other lasts 6–8 days. The difference is a small chemical add-on called DAC. If a vendor labels a vial just “CJC-1295” without telling you which form you’re getting, that’s the first red flag. We’ll walk you through the rest.

What you’re actually buying

CJC-1295 mimics the first 29 amino acids of human growth-hormone-releasing hormone — the brain signal that triggers GH pulses. ConjuChem developed it in the early 2000s as a once-weekly drug candidate (Rahman et al., 2026).

It activates the GH pathway in the pituitary. It does not bind the ghrelin pathway — that’s ipamorelin’s job. That’s why researchers stack the two together rather than choose one.

The thing that decides which CJC-1295 you have is the DAC group. DAC stands for Drug Affinity Complex. It’s a small chemical linker that covalently bonds to albumin in your blood (Memdouh et al., 2021). Albumin acts like a slow-release shuttle. Once the peptide is bound to it, the kidneys can’t filter it out fast.

• No-DAC (Modified GRF 1-29): 29 amino acids, half-life ~30 minutes, produces natural GH pulses.
• DAC: 30 amino acids plus the linker, half-life 6–8 days, produces sustained GH elevation.

Four buyer checks for CJC-1295

The general eight peptide-buyer criteria all apply. These four matter more for CJC-1295:

1. The label must say DAC or no-DAC

This is the single most important check. The vial and the CoA both have to tell you which variant you bought. No-DAC has CAS number 863288-34-0. DAC has a separate CAS registration.

A vendor selling “CJC-1295” without disambiguating is failing the most basic identity disclosure. Walk away.

2. The discontinuation history matters

ConjuChem halted CJC-1295 DAC clinical development around 2007. Public reporting attributes the decision in part to broader scrutiny of ConjuChem’s DAC pipeline after a fatal adverse event in a separate trial of CJC-1131, a different DAC-modified peptide.

The program was never revived. CJC-1295 has no current pharmaceutical sponsor. A vendor making clinical claims (“treats GH deficiency,” “reverses aging”) is in FDA enforcement territory.

3. Mass-spec must match the variant

For no-DAC, the theoretical mass is 3367.9 g/mol. The formula is C₁₅₂H₂₅₂N₄₄O₄₂. Peptides this big usually show up in mass-spec as multi-charge ions: observed [M+2H]²⁺ near 1684.9, or [M+3H]³⁺ near 1123.6. The calculated neutral mass should land at 3367.9 within standard tolerance.

The DAC variant has a different molecular weight because the linker adds mass. A CoA that reports 3367.9 for a vial labeled DAC is internally inconsistent — don’t buy from that vendor.

4. Storage and shipping are unforgiving

CJC-1295 ships lyophilized (freeze-dried) and stores at −20°C long-term. Once you reconstitute it, the no-DAC form has a usable window of about 30 days refrigerated at 2–8°C. That’s shorter than BPC-157 because CJC-1295 degrades faster in solution.

Vendors who sell pre-mixed liquid at room temperature are selling a product with a shelf life measured in days. The powder is what ships reliably.

CJC-1295 (no DAC)

Modified GRF 1-29 29 aa ~30 min t½

The no-DAC variant cited across the 2021–2024 anti-doping detection literature including Memdouh et al., 2021 and the 2026 JAAOS therapeutic peptides review. CAS 863288-34-0, MW 3367.9 g/mol, ≥99% HPLC purity, ISO 17025 third-party CoA on every lot.

View CJC-1295

2026 pricing benchmarks

CJC-1295 sits in the middle of the research-peptide cost curve. It’s longer than BPC-157 (15 aa) but shorter than tesamorelin (44 aa). The DAC modification adds synthesis cost on top of the no-DAC form. Research-grade retail in 2026:

• No-DAC, 5 mg vial: $50–$100 ($10–$20 per mg). Standard retail size.
• No-DAC, 10 mg vial: $80–$150 ($8–$15 per mg). Better per-mg value.
• DAC, 5 mg vial: $80–$150 ($16–$30 per mg). The conjugation step adds complexity.
• DAC, 10 mg vial: $130–$220 ($13–$22 per mg). Less commonly stocked.
• Multi-vial tiers: 10–25% off for 3- or 6-pack orders.

Below $40 per 5 mg no-DAC, or below $60 per 5 mg DAC, deserves a question. Each additional coupling step in a 29-amino-acid peptide is an opportunity for incomplete reaction. That means more impurities at the cheap end, where the purification step gets shortcut.

Is CJC-1295 legal to buy?

Yes, as a research reference compound. It’s not FDA-approved, never finished clinical development, and lives on the FDA’s bulks-not-eligible-for-503A-compounding lists. That closes the compounding-pharmacy channel for human use. It doesn’t affect research sales.

Three more things the legal status does:

• It tells you about the evidence base. No active pharmaceutical sponsor means no ongoing trials. Recent PubMed literature from 2020 to 2026 is dominated by anti-doping detection methods.
• It closes the compounding pharmacy channel. Pharmacies can’t prepare CJC-1295 for human use.
• It triggers WADA prohibition under Category S2. Validated LC-MS/MS methods detect CJC-1295 at sub-ng/mL in urine (Memdouh et al., 2021; Coppieters et al., 2022). Athletes are reliably detectable for no-DAC within hours and DAC for days.

Research-use sales operate under 21 CFR § 809.10(b)(9). Laboratory research stays legal. See peptides and the 2023 503A categorization for the deeper regulatory context.

Red flags specific to CJC-1295

Seven warning signs we’d skip:

• “CJC-1295” without DAC/no-DAC on the label. The single most basic identity disclosure.
• “CJC-1295 Pro,” “Long-Acting,” or branded variant names. The two real molecules are no-DAC and DAC. Anything else without a published structure is marketing.
• Pre-mixed liquid at room temperature. Shelf life in days, not weeks.
• Clinical claims on the product page. “Treats GH deficiency” or “reverses aging” are FDA enforcement territory for a discontinued-program compound.
• Missing CAS number. 863288-34-0 (no-DAC) should resolve in PubChem in 30 seconds.
• Mass-spec result that doesn’t match the variant. No-DAC = 3367.9, or [M+2H]²⁺ near 1684.9.
• Vendor’s in-house QC instead of third-party testing. Independent ISO 17025 verification is the research-grade standard.

CJC-1295 (no DAC)

10 mg ≥99% pure Lyophilized

Modified GRF 1-29, CAS 863288-34-0, MW 3367.9 g/mol. The same reference compound used across the 2020–2024 anti-doping detection literature and grouped in the 2026 Sports Medicine review of unapproved peptide therapies. COA with HPLC trace and mass-spec ships with every order.

Learn more

Frequently asked questions

Is CJC-1295 legal to buy?

Yes, as a research reference compound. It’s not FDA-approved, never finished clinical development, and sits on the FDA’s bulks-not-eligible-for-503A list. That closes compounding pharmacies. It doesn’t close research sales. It’s also on the WADA Prohibited List (S2).

DAC vs no-DAC — which one?

Two different molecules. DAC adds an albumin-binding linker that stretches the half-life to 6–8 days. No-DAC (Modified GRF 1-29) has a 30-minute half-life. Most current research use is the no-DAC form because it preserves pulsatile GH release. If the listing says only “CJC-1295,” ask before you buy.

How much does CJC-1295 cost?

No-DAC: $50–$100 for 5 mg, $80–$150 for 10 mg. DAC: $80–$150 for 5 mg, $130–$220 for 10 mg. The DAC variant costs more because the linker-conjugation step adds synthesis complexity. Below those ranges, purity is the trade-off.

Why was CJC-1295 DAC discontinued?

ConjuChem halted clinical development around 2007. Public reporting attributes the decision in part to scrutiny of the broader DAC pipeline after a fatal adverse event in a separate trial of CJC-1131. The program never restarted and CJC-1295 has no current sponsor.

CJC-1295 vs Ipamorelin

Different signaling pathways, complementary effects. CJC-1295 acts on the GH-releasing pathway. Ipamorelin acts on the ghrelin pathway and also blocks somatostatin, the brake on GH. Researchers stack them because the two pathways combine well. A 2026 review showed the combination improved muscle force in mouse models of glucocorticoid-induced muscle loss (Mayfield et al., 2026). See the CJC-1295 vs Ipamorelin comparison.

What should a CJC-1295 CoA show?

For no-DAC: CAS 863288-34-0, HPLC purity above 98% with chromatogram, mass-spec at MW ~3367.9 g/mol. The mass usually shows as multi-charge ions [M+2H]²⁺ near 1684.9 or [M+3H]³⁺ near 1123.6. Water content should be 2–8% by Karl Fischer titration. Counterion content is usually TFA at 5–15%. The DAC variant has a different MW because of the linker. The lab should be ISO 17025-accredited and named.